143 related articles for article (PubMed ID: 8833409)
1. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
Aviles A; Duque G; Talavera A; Guzman R
Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
[TBL] [Abstract][Full Text] [Related]
2. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
Avilés A; Neri N; Huerta-Guzmán J; Pérez F; Sotelo L
Leuk Lymphoma; 2004 Nov; 45(11):2247-51. PubMed ID: 15512813
[TBL] [Abstract][Full Text] [Related]
3. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Romaguera J; Rodriguez MA; Lee MS; Pate O; Sarris A; Younes A
Ann Oncol; 1994; 5 Suppl 2():73-7. PubMed ID: 7515650
[TBL] [Abstract][Full Text] [Related]
4. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
6. CHOP-Bleo plus interferon for stage IV low-grade lymphoma.
McLaughlin P; Cabanillas F; Hagemeister FB; Swan F; Romaguera JE; Taylor S; Rodriguez MA; Velasquez WS; Redman JR; Gutterman JU
Ann Oncol; 1993 Mar; 4(3):205-11. PubMed ID: 7682436
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.
Avilés A; Cleto S; Huerta-Guzmán J; Neri N
Eur J Haematol; 2001 Feb; 66(2):94-9. PubMed ID: 11168516
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
[TBL] [Abstract][Full Text] [Related]
9. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
11. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Enschede SH; Porter C; Venugopal P; Gregory SA
Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma.
Neri N; Avilés A; Cleto S; Díaz N; Talavera A; García EL; Díaz-Maqueo JC
J Hematother Stem Cell Res; 2001 Oct; 10(5):669-74. PubMed ID: 11672513
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
19. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
